New drug combo aims to boost myeloma treatment

NCT ID NCT05002816

Ongoing Disease control Sponsor: Yale University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether combining two approved drugs, belantamab mafodotin and elotuzumab, is safe and works better than either alone for multiple myeloma. About 24 adults whose cancer has returned or not responded to at least three prior treatments will receive the combination. The goal is to find the best dose and see if it improves response rates.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: belantamab mafodotin and elotuzumab
What this could lead to: If it works, this could offer a new, more effective treatment option for people with multiple myeloma who have not responded to other therapies.
What could go wrong: This is an early-phase trial with only 24 participants, so results may not apply to everyone. The drug combination may cause serious side effects, including eye problems and low blood counts.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

Contacts and locations

Locations

Yale New Haven Hospital

New Haven, Connecticut, 06512, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.